R-CHOP + and High-Dose Methotrexate (HM)

Article 1: CHOP-R and High-Dose Methotrexate In The Primary CNS Lymphoma Revisited. 10-Year Experience and 92 Patients From a Single Institution (2013)

Article 2: Patient Selection for High-Dose Methotrexate As Central Nervous System Prophylaxis in Diffuse Large B-Cell Lymphoma in Australia: Are We Getting It Right?

Conclusions: HDMTX was well-tolerated by patients, therefore can safely be administered as CNS prophylaxis under current hospital protocols. Application of the DSHNHL prognostic model identifies a different population of candidates for CNS prophylaxis compared to historical risk factors and may lead to better patient selection for this intervention

Article 3: Addition of high-dose methotrexate to standard treatment for patients with high-risk diffuse large B-cell lymphoma contributes to improved freedom from progression and survival but does not prevent central nervous system relapse

Combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) is regarded as standard care for diffuse large B-cell lymphoma (DLBCL) and upfront intensification of therapy is still controversial. The current study aimed to dertermine whether the addition of high-dose methotrexate (HDMTX) affects long-term outcomes and could also prevent central nervous system (CNS) relapse. Medical records of 480 patients with DLBCL treated between 1994 and 2013 at Rambam and Hadassah medical centers in Israel were reviewed; 130 (27%) had received HDMTX. Patients receiving HDMTX generally had higher International Prognostic Index (IPI) and CNS-IPI scores. HDMTX addition significantly improved progression free and overall survival (p = .001) and this advantage was maintained in multivariate analysis (HR for OS 0.3; 95% CI 0.19-0.47; p < .0001). Thirty-one (6.5%) patients had CNS relapse and in these cases high CNS-IPI, but not HDMTX treatment, was independently associated with CNS relapse (HR 1.2; 95% CI 1.2-11.5; p = .02). In conclusion, the addition of HDMTX to CHOP/RCHOP independently and significantly improved prognosis of patients with high-risk DLBCL, irrespective of their risk for CNS relapse.

Methotrexate

Side effects needing medical attention
Black, tarry stools; bloody vomit; diarrhea; sores in mouth or on lips; stomach pain; fever; chills; sore throat; unusual bleeding or bruising; blood in urine or dark urine; blurred vision; confusion; convulsions or seizures; cough; dizziness; drowsiness; headache; joint pain; shortness of breath; rash; swelling of feet or lower legs; unusual tiredness or weakness; yellowing of eyes and skin; loss of appetite; nausea or vomiting. The above side effects may be more likely to occur in very young and very old patients.

Side effects needing medical attention after stopping this medication
Blurred vision; convulsions or seizures; dizziness; drowsiness; headache; confusion; unusual tiredness or weakness.

Major side effects of low-dose methotrexate

Joel M Kremer, MDSection Editor:James R O’Dell, MDDeputy Editor:Paul L Romain, MD
INTRODUCTION

Methotrexate (MTX) use can be associated with a variety of adverse effects over a wide range of severity; the risk of most side effects is influenced by the MTX dose and treatment regimen. In rheumatoid arthritis (RA) and other disorders, MTX is administered as long-term, low-dose therapy, usually 7.5 to 25 mg weekly, unlike its use for treatment of malignant disease, where it is may be administered in a cyclic fashion in doses of 1 gram or more.
The most commonly observed side effects of MTX at doses typically used for the treatment of RA are rarely life-threatening, in contrast with the high doses used in the treatment of malignancies. Nevertheless, they may become clinically significant if they result in premature discontinuation or dose alteration of a drug that is the best therapeutic alternative for a given individual.

Potentially life-threatening hepatotoxicity, pulmonary damage, and myelosuppression may be seen with use of MTX as either high- or low-dose therapy, while nephrotoxicity is a manifestation of high-dose therapy that occurs rarely, if ever, with low-dose MTX treatment.

The major side effects of low-dose MTX are reviewed here. The use of low-dose MTX in patients with RA and other rheumatic diseases and the clinical use and adverse effects of high-dose MTX and related adverse effects are described separately. (See “Use of methotrexate in the treatment of rheumatoid arthritis” and “Therapeutic use and toxicity of high-dose methotrexate”.)

Resizing windows 10 partition

  1. Disable hybernation: run powercfg.exe /hibernate off
  2. Delete pagefile.sys in the file explorer
  3. Run c:\dir -h to confirm ‘hyberfil.sys’ and ‘pagefile.sys’ are deleted
  4. Run disk cleanup utility
  5. Clear recycle bin
  6. unplug internet
  7. restart
  8. Resize partition

If ‘not enough space available’ error is found, go to the Event log viewer and find out which file is stuck

Try launching the Event Viewer to see which individual files are blocking the partition shrink.

Once again, attempt to shrink the partition. You should get the “There is not enough space” error.
Launch Windows’ Event Viewer application.
In Event Viewer, go to Windows Logs > Application.
Find and Click a recent log of type Warning. It should have the message, “Error: during volume shrink initiated on volume Windows (C:) we failed to move a movable file extent.” (screenshot)
The Diagnostic details will give you the name of the “last unmovable file”
Delete this file (Simply send to recycle bin. I did not need a hard delete).
Try shrinking your volume again.
Repeat steps 2-7 until you successfully shrink your partition. (In my case, I had to do this 3 times, as I had 3 pdf files in my local Google Drive that were for some reason stuck as ‘unmovable’.).
Restore your deleted files.

https://superuser.com/questions/1063692/cannot-shrink-c-partition-not-enough-space

Conf: SfN19 Chicago

Session Type: Poster
Session Number: 340
Session Title: Software Tools: Analysis I
Session Date and Time: 10/21/2019 8:00:00 AM – 10/21/2019 12:00:00 PM
Location/Room: McCormick Place: Hall A

Presentation Time:  10/21/2019 11:00:00 AM –  10/21/2019 12:00:00 PM
Presentation Number:  340.16
Poster Board Number:  CC73
Abstract Control Number: 14195

Poster boards are six feet (1.8 m) wide and four feet (1.2 m) high. More information on preparing your poster, including poster templates, can be found on SfN.org.  Poster templates are provided as guidelines for creating a poster.  Posters are not required to follow a particular format. They should follow requirements for scientific rigor, outlined below. 

Layout (4 column)

  • Title: Prepare a banner for the top of the poster indicating the abstract title, author(s), affiliation(s), and the presentation number. Use lettering at least one-inch high.
  • Illustrations: Design figures for viewing from a distance and use clear, visible graphics and large type. Colors are effective if used sparingly; use dark colors on white or pale backgrounds and light colors on dark backgrounds. Figures should illustrate no more than one or two major points. However, simple figures are unnecessary. Make clear main points, but include detail for the aficionado. Indicate illustration sequences with numbers or letters at least one inch high. (Omit “Fig.” or “Figure.” This is unnecessary and occupies excess space).
  • Text
    • Each figure or table should have a heading of one or two lines in very large type stating the “take-home” message. Provide additional essential information below in a legend set in 16 point or larger type.
    • Minimize narrative. Integrate text that would normally appear in the body (Results and Discussion) of a manuscript in figure legends. Concisely describe not only the content of the figure, but also the derived conclusions. Place brief details of methodology at the end of each legend.
    • Use large type in short, separated paragraphs with unjustified (ragged right) margins. Numbered or bulleted lists are effective ways to convey a series of points. Do not set entire paragraphs in uppercase (all capitals) or boldface type.
    • Place an introduction at the upper left and a conclusion at the lower right, both in large type. It is rarely necessary to post a copy of the abstract.


T. Chen Fong and fMRI+ephys

Neuralink investor

Southern Alberta hall of fame

Order of canada

Simultaneous fMRI and Ephys

Simultaneous FMRI and electrophysiology in the rodent brain.

https://www.sciencedirect.com/science/article/pii/S0165027018301419

https://www.sciencedirect.com/science/article/pii/S0165027018301419

Ferromagnetic material free probe from neuronexus

ferromagnetic material (iron cobalt nickle)

Small animal MRI

Bruker Biospin 9.4T scan- ner (Bruker Medizintechnik, Karlsruhe, Germany) equipped with an actively shielded gradient coil. A quadrature volume transmitter coil (model: MT0381, inner diameter=86mm) was used for RF excitation. An actively-decoupled surface coil (model: MT0105-20) was placed di

9.4 T 210 ASZ (Varian, Inc. Palo Alto, USA) 

Small animal MRI in uCalgary: experimental imaging center (Jeff Dunn)

Dunn et al 2009: carbon electrode + MRI
Cam Teskey: Jeff Dunn’s collaborator

Correlative measurement study

OptoMRI: light modulated vaso dialation.
fMRI vs ephys agree and disagree
JoVE article on fMRI+glass electrode

Small animal MRI in uAlberta
https://www.invivonmr.ualberta.ca/Research/fees.php

uoc visit

jorn davidsen. fMRI paper. two network interactions. stability across subject. connect him to dan english.

christph simon. quantum effects in neuroscience. photons in the brain. network. cryptoprotein.

Wilten Nicola. hard drive theory. nature neuroscience paper. two oscillations. interneuron rings.

how to decode information from hippocampus and expose them.

# Committee
David Knudsen, David Park, Ania Harlick, Jo-Anne Brown, Claudia Gomes da Rocha,

# Funding
NIH-CANADA: Participation by Canadian Researchers in the NIH BRAIN Initiative
NSERC Discovery Grant: Aug 1 (intent), Nov 1 (application), instruction
NSERC CREATE Grant: Collaborative research and trainig experience training. $1.65M for 6 years
CFI: Canadian foundation for innovation (Sep 16)
Compute Canada: Nov 8
Albertainnovates.ca:
KECK foundation:
Simon’s foundation

# Equipment
NEUROPIXELS
STEREOTAX
MICRODRIVE
Surgical microscope

# Day 0 schedule

# Day 1 schedule

Talk, lecture (clustering)
meetings with David Knudsen, Jo-Ann Brown, Ania Harlick,
Lunch with students
Richard Frayne

# Day 2 schedule

Group questions: funding. research. impact. teaching. outreach
meetings with Wilten Nicola, Jorn Davidsen
Lunch with David Feder, David Hobil, Ania. Penetrating ground radio
Meetings with Christoph Simon, David Feder, David Hobil

# Day 3 schedule

Breakfast with T. Chen Fong with Jorn Davidsen, Wilten Nicola, David Park @ Calgary Golf & Country Club

Deciding programming language for computational physics course

Matlab vs. Python (Medium)

Python is free, Matlab is well documented and has simulink.

Mathwork’s answer to it

My decision: is Matlab available at UOC? No data

Matlab to python migration guide (Enthought)

I did the tutorial on google colab and very easy to write and run, without having to setup anything. this is how students should do their assignment and projects.

https://colab.research.google.com/drive/12Nk14JmuwkGA1Rv8pHhVlGdxl5iEAqxM#scrollTo=jfYvIWTQWTtW

Python with web interface. Offer hosting with herokuapp. how about jupyterhub account for students?

UOC uses desire2learn (linkedin learning) or D2L system. Students can submit .py files (or ipynb files). or through google colab which might be the easiest.

So give them projects in python and run it on google colab.